How to Identify a Pharmacophore  by Prinz, Heino
Given that the tail comprises only
40% of the total surface area of the
toxins and the fact this feature is highly
conserved across different cytotoxin fam-
ilies, the work by Perrins et al. raises
important questions about whymarine or-
ganisms go to the trouble to produce
complex macrocycles. Their observation
that the functionality of the tail segment
was significantly enhanced with the addi-
tion of an aromatic group (a para-methox-
yphenyl acetal protecting group), which is
in actuality an artifact of the chemical syn-
thesis, indicates that the macrocycle is
not entirely superfluous, but can be mod-
ified or substituted with alternative hydro-
phobicmoieties to help stabilize the actin-
drug complex. Cursory docking of the
most bioactive analog onto the structural
coordinates of actin in its reidispongiolide
A-bound conformation lends support to
this hypothesis (Figure 2). The aromatic
group could, in part, reconstitute impor-
tant hydrophobic interactions with the
shallow hydrophobic patch on actin that
is contacted by analogous regions of
many diverse barbed end-binding macro-
lides. Notably, this portion of the ring was
previously been described as a likely
component of the pharmacophore of
these compounds (Allingham et al.,
2006; Melville et al., 2007). Elaboration
of the tail segment with other hydrophobic
moieties in place of this portion of the ring
could serve a dual role of stabilizing the
interaction of the tail with actin, likely by
reducing the entropy of binding, and
providing a scaffold for appending cell-
specific targeting ligands or optical
probes.
In addition to the direct therapeutic ap-
plications, the work of investigators like
Perrins et al. could also stimulate novel
areas of interest in the development of ac-
tin-binding ligands as diagnostic or prog-
nostic tools based on alterations of the
cytoskeletal properties of tumor cells.
On a more general note, such work may
have important implications on the design
of drugs that are intended to disrupt pro-
tein-protein interactions based on the
filament-disrupting mechanism of these
compounds.
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The inhibition of chitinases by argifin and progressively dissected analogs had been studied by a combination
of kinetic and crystallographicmethods (Andersen et al., 2008). This work also leads to a general understand-
ing of structure-activity relationships for inhibitors with one distinct pharmacophor.In this issue of Chemistry & Biology, van
Aalten and colleagues describe the identi-
fication of dimethylguanylurea as a phar-
macophor for family 18 chitinases (Ander-
sen et al., 2008). Dimethylguanylurea
forms the terminus of the major side chain
of argifin, a modified cyclopentapeptide
which is a potent chitinase inhibitor. Inhindsight, that finding may have been ex-
pected, since the molecule dimethylgua-
nylurea is to the molecule argifin what
the symbol + is to the symbol \. The
beauty of this work lies in the complete
set of methods applied. Five successively
shortened linear fragments of argifin were
synthesized. Their activity was testedChemistry & Biology 15, March 200against family 18 chitinases from three
different species, fungus, human, and
mouse. Crystals of one of these (chitinase
B1 from the fungus Aspergillus fumigatus)
were soaked with those fragments. The
X-ray structures of the complexes were
solved and compared to the known com-
plex with argifin (Houston et al., 2002). All8 ª2008 Elsevier Ltd All rights reserved 207
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activity. This study is a textbook-like
case to decipher a structure-activity rela-
tionship, and it sets a benchmark for the
molecular identification of conceptual
pharmacophors (Ehrlich, 1909). It may
be regarded as the fruit of several years
of experience with the enzyme and with
the techniques applied.
Taken by itself, dimethylguanylurea is
not much of a drug. Its affinity was in
the millimolar range. Of three chitinases
tested, its affinity for the fungal chitinase
was highest, but even there, the mea-
sured IC50 value only was 0.5 mM. This
is a 20,000-fold decrease in affinity as
compared to argifin. However, that argu-
ment may be reversed: the natural prod-
uct argifin has incorporated tremendously
effective modifications of the pharmaco-
phor dimethylguanylurea which led to an
increase in affinity by a factor 20,000.
Which steps attribute to the high affinity
of argifin? How rigid are the bound struc-
tures? How flexible is the pharmacophor
when bound to the active site? The
answers obviously are of general interest.
The largest change in affinity (by a factor
of 200) was observed when the intact
argifin, the cyclopentapeptide, was com-
pared with a liner tetrapeptide, missing
one aspartic acid cut off opposite to the
pharmacophore side chain, but otherwise
identical. That large affinity change was
by nomeans reflected in the crystal struc-
ture, where both inhibitors roughly oc-
cupy the same sites and were involved
in basically the same molecular interac-
tions. The authors rightfully argue that
the different affinities likely result from en-
tropic penalties which will accompany
the binding of the flexible tetrapeptide to
give the same backbone structure (within
0.6 A˚) as argifin. Or, putting it as the not208 Chemistry & Biology 15, March 2008 ª2unexpected simplified take-home mes-
sage: a cyclic peptide has a much higher
affinity toward a target protein as com-
pared to the linear peptide, when the con-
formations fit. Flexibility comes at a price.
When that tetrapeptide was truncated
by an N-terminal alanine residue not in-
volved in significant interactions with the
enzyme active site, the resulting affinity
of the tripeptide was only marginally
lower. This finding was in accordance
with minor changes detected in the crys-
tal structure of the complex. But when
a C-terminal aspartic acid involved in the
network of hydrogen bonds also was
removed, considerable changes (up to
3.4 A˚) in the backbone of the bound pep-
tide were observed. These changes were
accompanied with major changes in hy-
drogen bonds for the peptide, but not for
the pharmacophor. The affinity for the
dipeptide was decreased, but only by
a factor 2.4 as compared to the tripeptide.
The different orientation of the dipeptide
backbone obviously had led to an ener-
getically more favorable array of molecu-
lar interactions. Again, there is a simple
and not unexpected take-homemessage.
Modification of a small molecule may lead
to a different orientation of that molecule
within the same protein site. That different
orientation may leave parts of that mole-
cule (in this case the pharmacophor with
its four hydrogen bonds and one stacking
interaction with one chitinase tryptophan)
unaffected. Further truncation of the di-
peptide toward the acetylated single
amino acid monopeptide and finally to
dimethylguanylurea resulted in affinities
lower by factors of 6.7 and 6.2, respec-
tively. This was to be expected and was
in full accordance with the decreasing
number of molecular interactions de-
tected in the crystal structures.008 Elsevier Ltd All rights reservedWith one exception, the amino acids
interacting specifically with dimethylgua-
nylurea are conserved in evolution. The
ranking of argifin fragments is in agree-
ment with chitin-argifin interactions iden-
tified in a previous mutagenesis study
(Rao et al., 2005a). The same active site
residues of chitinases employed in the
detection of argifin interactions had been
identified previously for other family 18
chitinase inhibitors (Terwisscha van
Scheltinga et al., 1994; Rao et al.,
2005b). Therefore, the results are in ac-
cordance with the literature. With this
background, the contribution of van Aal-
ten and his group (Andersen et al., 2008)
may be regarded as one rare example of
an original paper with conclusive results.
Of course, dimethylguanylurea with its
low affinity is not a drug. It is a small prom-
ising pharmacophor which may be used
as a building block for future syntheses
of enzyme inhibitors.
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